Back to top
more

DuPont de Nemours (DD)

(Real Time Quote from BATS)

$73.39 USD

73.39
3,785,306

+2.48 (3.50%)

Updated Aug 5, 2025 01:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 7% (230 out of 246)

Industry: Chemical - Diversified

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Compared to Estimates, DuPont de Nemours (DD) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for DuPont de Nemours (DD) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

DuPont's Earnings & Sales Top Estimates in Q2 on Higher Volumes

by Zacks Equity Research

DD's Q2 earnings and sales top estimates, fueled by volume growth in ElectronicsCo and IndustrialsCo segments.

Zacks Equity Research

DuPont de Nemours (DD) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

DuPont de Nemours (DD) delivered earnings and revenue surprises of +5.66% and +1.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tronox (TROX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tronox (TROX) delivered earnings and revenue surprises of -600.00% and -5.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Kronos Worldwide (KRO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Kronos Worldwide (KRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

DuPont de Nemours (DD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

DuPont de Nemours (DD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

DuPont Launches FilmTec Hypershell for Energy-Efficient Dairy Processing

by Zacks Equity Research

DuPont's FilmTec Hypershell XP RO-8038 boosts dairy processing with up to 50% more productivity or 50% less energy use.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Anindya Barman headshot

3 Diversified Chemical Stocks to Watch Amid Demand Headwinds

by Anindya Barman

Soft demand in specific markets and the sluggishness in China and Europe pose headwinds for the Zacks Chemicals Diversified industry. DD, ALB and KRO are poised to navigate the industry challenges.

Zacks Equity Research

DD Adds Sterile Packaging Capacity at Costa Rica Manufacturing Plant

by Zacks Equity Research

DuPont's Costa Rica expansion introduces sterile healthcare packaging, a first for the region's medical device industry.

Zacks Equity Research

Here's Why You Should Hold DuPont Stock in Your Portfolio for Now

by Zacks Equity Research

Innovation, cost savings and healthcare acquisitions support DD as it navigates weak demand and hefty separation costs in 2025.

Anindya Barman headshot

DOW vs. DD: Which Chemical Giant Deserves a Spot in Your Portfolio?

by Anindya Barman

Dow tackles weak demand with cost cuts and cash actions, while DuPont gains from acquisitions in healthcare and innovation.

Zacks Equity Research

DuPont Achieves 100% Renewable Electricity in EU Operations

by Zacks Equity Research

DD hits 100% renewable electricity for EU operations, marking a major step toward its 2050 net-zero emissions goal using RECs and solar installations.

Zacks Equity Research

DuPont Launches AmberChrom TQ1 Resin for Biopharma Applications

by Zacks Equity Research

DD launches AmberChrom TQ1 resin, boosting oligonucleotide and peptide purification with high capacity, purity, and scalability.

Zacks Equity Research

DuPont's Q1 Earnings Surpass Estimates, Revenues Increase Y/Y

by Zacks Equity Research

DD continues to benefit from sustained strength in the electronics markets, along with robust demand in the healthcare and water end markets.

Zacks Equity Research

DuPont de Nemours (DD) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

DuPont de Nemours (DD) delivered earnings and revenue surprises of 8.42% and 0.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DuPont Gears Up for Q1 Earnings: What's in the Offing for the Stock?

by Zacks Equity Research

DD is expected to have benefited from its innovation-driven investment, productivity actions and acquisitions amid pricing pressures in Q1.

Zacks Equity Research

Tronox (TROX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Tronox (TROX) delivered earnings and revenue surprises of -850% and 3.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

DuPont de Nemours (DD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

DuPont de Nemours (DD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

LyondellBasell (LYB) Q1 Earnings Miss Estimates

by Zacks Equity Research

LyondellBasell (LYB) delivered earnings and revenue surprises of -8.33% and 1.10%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DuPont to Showcase Overlaminate Innovations at ISA Expo in Las Vegas

by Zacks Equity Research

DD's Tedlar will feature multiple film types that provide extended lifespans even in extreme outdoor environments.

Zacks Equity Research

DuPont Introduces Silver Nanowire Products in South Korea

by Zacks Equity Research

DD products using silver nanowire technology are transforming automotive interiors, powering the next generation of in-mold electronics.